What is Genisphere?
Genisphere is a biotechnology company dedicated to pioneering advancements in rare disease therapies through its proprietary 3DNA Precision Medicine Platform. This unique nanoscale scaffold, constructed from synthetic DNA, is engineered for precise and targeted intracellular delivery of therapeutic agents. The company's strategic focus includes developing treatments for neuroinflammatory diseases, actively pursuing collaborations to enhance drug delivery systems' efficacy and safety. Genisphere's mission is to maximize its platform's potential across various medical conditions, including neurodegenerative disorders and cancers, by fostering strategic partnerships within academic and industrial sectors.
How much funding has Genisphere raised?
Genisphere has raised a total of $13.2M across 4 funding rounds:
Private Equity
$2M
Private Equity
$4M
Unspecified
$7M
Debt
$150K
Private Equity (2014): $2M with participation from Corporate Fuel Securities
Private Equity (2015): $4M led by Lankenau Institute for Medical Research
Unspecified (2017): $7M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Key Investors in Genisphere
Corporate Fuel Securities
Corporate Fuel Securities is an investment bank providing strategic advisory and capital raising services, likely focusing on middle-market companies across various sectors including healthcare.
Lankenau Institute for Medical Research
The Lankenau Institute for Medical Research is an organization dedicated to advancing medical science and research, suggesting a focus on innovative healthcare and therapeutic development.
What's next for Genisphere?
The recent major strategic investment signals a pivotal growth phase for Genisphere, likely enabling the company to accelerate the development and clinical validation of its 3DNA platform. This capital infusion is expected to bolster research and development efforts, potentially expanding its therapeutic pipeline and forging new strategic alliances. Genisphere's focus on precision medicine for rare diseases positions it to address significant unmet medical needs, with future endeavors likely centered on advancing its lead candidates through regulatory pathways and exploring broader applications of its innovative drug delivery technology.
See full Genisphere company page
